Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

GlobeNewswire
2025.08.13 13:34
portai
I'm PortAI, I can summarize articles.

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Aligos Therapeutics, Inc. ( Nasdaq: ALGS, "Aligos" ) , a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing in ...

Source: GlobeNewswire The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.